Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Capital Expenditures (2016 - 2025)

Orthopediatrics has reported Capital Expenditures over the past 10 years, most recently at -$10.5 million for Q4 2025.

  • Quarterly results put Capital Expenditures at -$10.5 million for Q4 2025, up 27.64% from a year ago — trailing twelve months through Sep 2025 was -$4.0 million (down 113.01% YoY), and the annual figure for FY2023 was $16.9 million, up 68.26%.
  • Capital Expenditures for Q4 2025 was -$10.5 million at Orthopediatrics, down from $2.8 million in the prior quarter.
  • Over the last five years, Capital Expenditures for KIDS hit a ceiling of $16.3 million in Q4 2023 and a floor of -$14.5 million in Q4 2024.
  • Median Capital Expenditures over the past 5 years was $2.8 million (2021), compared with a mean of $1.8 million.
  • Peak annual rise in Capital Expenditures hit 3222.75% in 2023, while the deepest fall reached 1019.83% in 2023.
  • Orthopediatrics' Capital Expenditures stood at $1.6 million in 2021, then plummeted by 131.99% to -$523000.0 in 2022, then surged by 3222.75% to $16.3 million in 2023, then crashed by 188.94% to -$14.5 million in 2024, then rose by 27.64% to -$10.5 million in 2025.
  • The last three reported values for Capital Expenditures were -$10.5 million (Q4 2025), $2.8 million (Q3 2025), and $3.4 million (Q2 2025) per Business Quant data.